News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dicerna Pharmaceuticals (DRNA) Initiates Phase 1 Study Of DCR-MYC In Patients With Solid Tumors And Hematological Malignancies



4/17/2014 9:46:01 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced the initiation of a Phase 1 dose-escalating clinical study of DCR-MYC, (also known as DCR-M1711), in patients with solid tumors, multiple myeloma, or lymphoma. DCR-MYC, Dicerna’s first drug candidate to enter clinical testing, is a Dicer Substrate siRNA (DsiRNA) that targets the driver oncogene MYC, which is central to the growth of many hematologic and solid tumor malignancies. Dicerna is investigating DCR-MYC in a variety of tumor types with the initial focus on hepatocellular carcinoma.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES